10:39 AM EDT, 06/10/2024 (MT Newswires) -- Repare Therapeutics ( RPTX ) said Monday the first patient was dosed in its camonsertib monotherapy non-small cell lung cancer expansion of a clinical trial.

The trial will investigate the safety, tolerability and anti-tumor activity of camonsertib alone or in combinations, the company said.

The expansion phase is expected to enroll up to 20 patients.

Repare said it expects a potential data readout in 2025.